Atrial fibrillation (AF) is a very common diagnosed arrhythmia and catheter ablation is an effective treatment, but recurrence occurs after catheter ablation and remains a medical challenge. MicroRNAs can be easily detected in the circulation, and they are epigenetic regulators in many biological processes; their usefulness as biomarkers of risk stratification in patients with AF was investigated.
Researchers from University Hospital Bonn presented data from a study that aimed to evaluate the significance of serum levels of the endoplasmic-reticulum-stress chaperone GRP78 in patients undergoing coronary angiography for suspected coronary artery disease (CAD).
There is a lack of biomarkers for disease activity in aortic stenosis (AS). On the other hand, citrullination is involved in many chronic inflammatory processes and citrullinated proteins have been found within atherosclerotic plaque.
GSK plc presented data on the discovery of a selective and potent lead series for G protein-coupled receptor kinase 2 (GRK2) inhibition for the potential treatment of heart failure. Heart failure remains a leading cause of morbidity and mortality worldwide.
Southern Marine Science and Engineering Guangdong Laboratory and Guangdong Medical University have disclosed peptides acting as angiotensin-converting enzyme (ACE) inhibitors reported to be useful for the treatment of hypertension.
Rhizen Pharmaceuticals and Incozen Therapeutics have synthesized new cyclin-dependent kinase (CDK) inhibitors reported to be useful for the treatment of atherosclerosis, autoimmune disease, cancer, Alzheimer's disease, pulmonary fibrosis, inflammatory disorders, psoriasis and rheumatoid arthritis, among other disorders.
Using a knock-in mouse model of Brugada syndrome (BrS) with an SCN5A mutation identified in multiple BrS families (Scn5aG1746R/+), a team of scientists from various research institutions evaluated the effects of upregulation of MOG1 (ran guanine nucleotide release factor, RanGNRF) via adeno-associated virus serotype 9 (AAV9) vector delivery on BrS features.
Researchers from Cantargia and Johns Hopkins University School of Medicine presented data from a preclinical study evaluating an IL-1 receptor accessory protein (IL-1RAP)-blocking antibody, CAN-10, in a model of acute coxsackievirus B3 (CVB3) myocarditis.
RSS
